
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is a commercial-stage medical technology company focused on improving the vision of cataract surgery patients. With a strong product offering and a wide market potential, the company has the potential for impressive growth in the coming years. Despite some recent setbacks, including lower utilization and margin contraction, there are potential upside drivers such as faster LDD installed base growth and higher utilization that could lead to improved financial performance and higher share value. However, there are still risks involved in the adoption of the product, competition in the market, and the potential need for a dilutive financing round. Overall, based on their expected growth and valuation, analysts maintain a positive outlook on RxSight's stock.
Bears say
RxSight is experiencing underlying weakness in sales and utilization attributable to competitive trialing and their new collaboration with Alcon. They also face limited adoption and potential for a dilutive financing round as well as disappointing commercial execution in a market with increased competition. The fact that they have missed revenue expectations in previous quarters and consistently underperformed in terms of LDD and LAL sales also indicates a negative outlook for the company.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares